Currently, three drugs (JNJ-61610588, CA-170 and CI-8993) targeting VISTA are ongoing clinical trials, other VISTA inhibitors like 13F3, αVISTA, 6809‐0223, HMBD-002, MIH63 have tested their therapeutic effect in mouse tumor models, most of them exert by restoring or enhancing the function of immune cells, and promoting the production of cytokines like IL-4, IFN-γ and TNF-α. This evidence concerns the gene IFNG and neoplasm.